Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio TechROCO:1295 -0.51%44 Return-on-Tangible-Equity is 13.22% as of Dec. 2025, which is 18% below its 10-year median of 16.04. GuruFocus rates ROCO:1295 with a GF Score™ of 44/100. The stock has 10 warning signs investors should review. Among 1,200 Biotechnology companies, Synbio Tech ranks better than 89.5% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Synbio Tech's annualized net income for the quarter that ended in Dec. 2025 was NT$169 Mil. Synbio Tech's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,279 Mil. Therefore, Synbio Tech's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 13.22%.
The historical rank and industry rank for Synbio Tech's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:1295'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.77 Med: 16.04 Max: 20.17
Current: 15.13
During the past 6 years, Synbio Tech's highest Return-on-Tangible-Equity was 20.17%. The lowest was 10.77%. And the median was 16.04%.
ROCO:1295's Return-on-Tangible-Equity is ranked better than 89.5% of 1200
companies
in the Biotechnology industry
Industry Median: -42.305
vs ROCO:1295: 15.13
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Synbio Tech Return-on-Tangible-Equity Related Terms
Synbio Tech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Synbio Tech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1295 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Synbio Tech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Synbio Tech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.22% mean?
Synbio Tech (ROCO:1295) has a Return-on-Tangible-Equity of 13.22% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synbio Tech and its competitors. This is 18% below median its historical median of 16.04. Over the past decade, Synbio Tech's Return-on-Tangible-Equity has ranged from 10.77 to 20.17. According to the industry distribution chart, Synbio Tech ranks #126 out of 1200 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Synbio Tech's Return-on-Tangible-Equity too high?
Synbio Tech's current Return-on-Tangible-Equity of 13.22% is 18% below median its 10-year median of 16.04. Over the past 10 years, this metric has ranged from a low of 10.77 to a high of 20.17. Based on the distribution chart, Synbio Tech ranks #126 out of 1200 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Synbio Tech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Synbio Tech ranks #126 out of 1200 companies for Return-on-Tangible-Equity. This places Synbio Tech in the top 11% of its industry — outperforming the majority of peers. Historically, Synbio Tech's own Return-on-Tangible-Equity has ranged from 10.77 to 20.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synbio Tech and its competitors. Synbio Tech's current Return-on-Tangible-Equity is 13.22%, which is 18% below median its own 10-year median of 16.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Synbio Tech (ROCO:1295) has a current Return-on-Tangible-Equity of 13.22%. The current Return-on-Tangible-Equity is 13.22%, which is 18% below median its 10-year median of 16.04. Synbio Tech's overall GF Score™ is 44/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current Return-on-Tangible-Equity is 13.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
44GF Score
Get the complete analysis for ROCO:1295
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
